1BP-LSD

Pre-existing cardiovascular disease, Uncontrolled hypertension

LSD, the active metabolite, produces moderate tachycardia and hypertension. Individuals with pre-existing cardiovascular conditions face elevated risk from these hemodynamic effects.

Epilepsy, Seizure disorders

Psychedelic cortical excitation may lower seizure threshold. The interaction between psychedelic-induced cortical excitation and seizure disorders has not been systematically studied but warrants caution.

Schizophrenia, Schizoaffective disorder, Family history of psychotic disorders

Personal or family history of psychosis, schizophrenia, or schizoaffective disorder. LSD-class psychedelics acting through 5-HT2A receptor agonism can precipitate acute psychotic episodes and may trigger the onset of chronic psychotic illness in genetically predisposed individuals.

Bipolar disorder with psychotic features

Risk of manic or psychotic episode precipitation in individuals with bipolar disorder, particularly those with a history of psychotic features.

Pregnancy, Breastfeeding

No safety data exist for any lysergamide during pregnancy or lactation. The absence of data precludes any safety assurance.

Current lithium use

Current lithium use is associated with significantly increased risk of seizures and severe adverse reactions during psychedelic experiences. This interaction is consistently identified across user surveys and clinical reports.

Current MAOI use

Current use of monoamine oxidase inhibitors risks severe serotonergic potentiation with unpredictable duration and intensity through serotonin accumulation and reduced LSD metabolism.

Current mood stabilizer use

Current mood stabilizer use is associated with increased risk of challenging psychedelic experiences, per survey data from Simonsson et al. 2023.